See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, there is no specific frequency for monitoring patients on lurbinectedin for late side effects that has been established. The drug's usage and monitoring would typically be determined by a healthcare professional, taking into account the patient's individual needs and circumstances.

Lurbinectedin is a novel anticancer drug that has been approved by the European Medicines Agency (EMA) for the treatment of adult patients with certain types of relapsed or refractory small cell lung cancer (SCLC) [1]. The drug functions by inhibiting the transcriptional activity of oncogenic fusion proteins and other transcription factors, thereby preventing the growth and proliferation of cancer cells [1].

As with any medication, lurbinectedin can cause side effects, some of which may be severe or long-lasting. Common side effects of lurbinectedin include fatigue, nausea, vomiting, diarrhea, constipation, decreased appetite, and peripheral neuropathy [1]. Late side effects, or those that occur after treatment has been completed, may include secondary malignancies, cardiovascular complications, and other long-term health issues [2].

Healthcare professionals are responsible for monitoring patients on lurbinectedin for both acute and late side effects. The frequency and duration of monitoring would depend on the individual patient's risk factors, treatment history, and other relevant factors. Patients should be advised to report any new or worsening symptoms to their healthcare provider as soon as possible [2].

In summary, there is no universally recommended frequency for monitoring patients on lurbinectedin for late side effects. The monitoring schedule should be tailored to each patient's individual needs and circumstances. Healthcare professionals play a crucial role in identifying and managing side effects, both during and after treatment.

Sources:

1. European Medicines Agency. (2020). Zepzelca: Summary of product characteristics. Retrieved from <https://www.ema.europa.eu/en/documents/product-information/zepzelca-epar-product-information_en.pdf>
2. National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Retrieved from <https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf>
3. DrugPatentWatch. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>